Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296866> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4286296866 endingPage "3590" @default.
- W4286296866 startingPage "3590" @default.
- W4286296866 abstract "3590 Background: Co-occurring alterations (COAs) in the HER2 and MAPK pathway are rare in mCRC. RAS, HER2 and BRAF alterations have been associated with resistance to EGFR inhibitor therapy (EGFR-mab). Typical co-occurring mutually exclusive gene mutations such as in KRAS and BRAF have been reported. This study aims to evaluate the prevalence of co-occurring alterations in the MAPK pathway or across MAPK/ HER2 and correlate to outcomes in patients with mCRC treated with EGFR-mab. Methods: This is a retrospective study of patients with mCRC within the Mayo Clinic database who have available blood-based NGS Guardant 360 data (September 2017-November 2021) and contained co-alterations in the MAPK pathway or across MAPK/ HER2. MSI-high cases were excluded. Typical-RAS was defined as alterations in codons 12, 13, 59, 61, 117, and 146 of KRAS, HRAS, and NRAS. Atypical-RAS alterations were considered mutations at other codons of these genes. Patient characteristics, specific mutations, and outcome data were assessed. Results: 692 patients (pts) with mCRC were identified and 66 (9.5%) of those had COAs detected. 59/66 pts had clinical data available. Median age was 52 years, 55.9% were male, and 61.0% had left-sided tumors. The frequency of detected alterations was: BRAF-V600E (7.3%), BRAF-non-V600E (7%), BRAF-amplification (3.04%), RAS-typical (39.5%), RAS-atypical (2.1%), HER2 amp (0.5%), HER2-mutation (1.2%) and PIK3CA (13%). COAs are described in the table. Twenty-three pts received EGFR-mab; COAs developed in 19 of them after progression on EGFR-mab. Four pts received EGFR-mab with documented COAs at baseline with none of them responding to treatment. Conclusions: COAs in MAPK and MAPK/ HER2 pathway are not uncommon in pts with mCRC emphasizing on the importance and feasibility of blood based NGS vs. selected gene testing. In pts with prior EGFR-mab treatment, COAs were detected after progression on treatment in the majority of pts, suggesting a mechanism of secondary treatment resistance. Further data including prospective validation is warranted. [Table: see text]" @default.
- W4286296866 created "2022-07-21" @default.
- W4286296866 creator A5016536540 @default.
- W4286296866 creator A5019091131 @default.
- W4286296866 creator A5034301426 @default.
- W4286296866 creator A5050060726 @default.
- W4286296866 creator A5054238636 @default.
- W4286296866 creator A5056756269 @default.
- W4286296866 creator A5059366804 @default.
- W4286296866 creator A5064791048 @default.
- W4286296866 creator A5065927929 @default.
- W4286296866 creator A5072330329 @default.
- W4286296866 creator A5074891676 @default.
- W4286296866 date "2022-06-01" @default.
- W4286296866 modified "2023-10-12" @default.
- W4286296866 title "Co-occurring alterations across molecular pathways in metastatic colorectal cancer (mCRC)." @default.
- W4286296866 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3590" @default.
- W4286296866 hasPublicationYear "2022" @default.
- W4286296866 type Work @default.
- W4286296866 citedByCount "0" @default.
- W4286296866 crossrefType "journal-article" @default.
- W4286296866 hasAuthorship W4286296866A5016536540 @default.
- W4286296866 hasAuthorship W4286296866A5019091131 @default.
- W4286296866 hasAuthorship W4286296866A5034301426 @default.
- W4286296866 hasAuthorship W4286296866A5050060726 @default.
- W4286296866 hasAuthorship W4286296866A5054238636 @default.
- W4286296866 hasAuthorship W4286296866A5056756269 @default.
- W4286296866 hasAuthorship W4286296866A5059366804 @default.
- W4286296866 hasAuthorship W4286296866A5064791048 @default.
- W4286296866 hasAuthorship W4286296866A5065927929 @default.
- W4286296866 hasAuthorship W4286296866A5072330329 @default.
- W4286296866 hasAuthorship W4286296866A5074891676 @default.
- W4286296866 hasConcept C104317684 @default.
- W4286296866 hasConcept C1167327 @default.
- W4286296866 hasConcept C121608353 @default.
- W4286296866 hasConcept C126322002 @default.
- W4286296866 hasConcept C143998085 @default.
- W4286296866 hasConcept C184235292 @default.
- W4286296866 hasConcept C21790070 @default.
- W4286296866 hasConcept C2776470698 @default.
- W4286296866 hasConcept C2781187634 @default.
- W4286296866 hasConcept C501734568 @default.
- W4286296866 hasConcept C502942594 @default.
- W4286296866 hasConcept C526805850 @default.
- W4286296866 hasConcept C54355233 @default.
- W4286296866 hasConcept C57074206 @default.
- W4286296866 hasConcept C71924100 @default.
- W4286296866 hasConcept C86803240 @default.
- W4286296866 hasConceptScore W4286296866C104317684 @default.
- W4286296866 hasConceptScore W4286296866C1167327 @default.
- W4286296866 hasConceptScore W4286296866C121608353 @default.
- W4286296866 hasConceptScore W4286296866C126322002 @default.
- W4286296866 hasConceptScore W4286296866C143998085 @default.
- W4286296866 hasConceptScore W4286296866C184235292 @default.
- W4286296866 hasConceptScore W4286296866C21790070 @default.
- W4286296866 hasConceptScore W4286296866C2776470698 @default.
- W4286296866 hasConceptScore W4286296866C2781187634 @default.
- W4286296866 hasConceptScore W4286296866C501734568 @default.
- W4286296866 hasConceptScore W4286296866C502942594 @default.
- W4286296866 hasConceptScore W4286296866C526805850 @default.
- W4286296866 hasConceptScore W4286296866C54355233 @default.
- W4286296866 hasConceptScore W4286296866C57074206 @default.
- W4286296866 hasConceptScore W4286296866C71924100 @default.
- W4286296866 hasConceptScore W4286296866C86803240 @default.
- W4286296866 hasIssue "16_suppl" @default.
- W4286296866 hasLocation W42862968661 @default.
- W4286296866 hasOpenAccess W4286296866 @default.
- W4286296866 hasPrimaryLocation W42862968661 @default.
- W4286296866 hasRelatedWork W2123429489 @default.
- W4286296866 hasRelatedWork W2141202463 @default.
- W4286296866 hasRelatedWork W2155461614 @default.
- W4286296866 hasRelatedWork W2164992866 @default.
- W4286296866 hasRelatedWork W2741144734 @default.
- W4286296866 hasRelatedWork W2741536934 @default.
- W4286296866 hasRelatedWork W3022164378 @default.
- W4286296866 hasRelatedWork W3089798411 @default.
- W4286296866 hasRelatedWork W4200179277 @default.
- W4286296866 hasRelatedWork W4308401882 @default.
- W4286296866 hasVolume "40" @default.
- W4286296866 isParatext "false" @default.
- W4286296866 isRetracted "false" @default.
- W4286296866 workType "article" @default.